While the first quarter was a challenging quarter, it underscores the importance of building a strong pipeline and effectively launching new products,
While the first quarter was a challenging quarter, it underscores the importance of building a strong pipeline and effectively launching new products,
Given our products, pipeline, and the fact that we expect no major patent expirations for the rest of this decade, Lilly is uniquely positioned to deliver sustained earnings growth. For 2006, we anticipate earnings per share of 3.10 to 3.20, which represents 8 to 12 growth compared with expected 2005 adjusted earnings. This growth rate is nearly double the average Wall Street consensus forecast for large-cap pharmaceutical companies.
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.
© 2020 Inspirational Stories
© 2020 Inspirational Stories